Untitled

Borin, Marie T.; Khare, S. S.; Beihn, Robert M.; Jay, Michael

doi:10.1023/a:1015842600189

Cited by 33 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One way in which kinetics have been measured with a single photon emitter was when the kinetics of interest were of the dosage form rather than of the drug. The tracer was included in a solid formulation in a way that reliably traced the solid [53,[119][120][121][122][123][124][125][126]. Quantification of the tracer was not required.…”

Section: Drug Kineticsmentioning

confidence: 99%

Regional Distribution and Kinetics of Inhaled Pharmaceuticals

Berridge

Lee²,

Heald³

2000

CPD

View full text Add to dashboard Cite

Drug biodistribution is often secondary to drug action. However, drugs that have a topical action and are deposited into the airway by inhalation are dependent on effective deposition at the intended site of action. Measurement of the distribution of such drugs in the airway is a useful tool. Distribution data can help to interpret clinical results, to evaluate products relative to each other, to optimize a new drug formulation, and to choose effective drug delivery methods. Imaging of radiotracers is the only means available to measure drug deposition throughout the lungs, nasal passages, and sinuses. There are several approaches to imaging drug deposition. Planar imaging has been the most used method, but SPECT and PET imaging are beginning to be applied effectively. The properties of non-drug tracers, labeling of drugs, evaluation of distribution patterns, and quantification of deposited drugs are important issues that have been addressed. Imaging has been shown to be a powerful technique to evaluate and to speed development of inhaled drugs. This review explores the most recent advances and issues with an emphasis on drug development.

show abstract

Section: Drug Kineticsmentioning

confidence: 99%

Regional Distribution and Kinetics of Inhaled Pharmaceuticals

Berridge

Lee²,

Heald³

2000

CPD

View full text Add to dashboard Cite

show abstract

“…Other bioequivalence studies have found that the addition of ibuprofen can lead to an increase in the rate of absorption of acetaminophen [15,16]. The ingestion of food can alter the rate and extent of drug absorption and this has been shown to occur with both acetaminophen and ibuprofen previously [16][17][18][19][20][21][22][23][24]. This study aimed to determine and compare the pharmacokinetic parameters (C max , AUC (0-t) , AUC (0-∞) , t max , K el , and t 1/2 ) of the four fixed-dose formulations of acetaminophen and ibuprofen (FDC500/150, FDC325/97.5, Sachets, Oral Suspension) in either fed or fasting conditions.…”

Section: Introductionmentioning

confidence: 99%

A Single Dose, Four-Way, Open-Label Bioavailability Study of Oral Acetaminophen and Ibuprofen Combinations (Maxigesic®) under both Fasting and Fed Conditions

Aitken¹,

Salem²,

Stănescu³

et al. 2018

J Bioequiv Availab

View full text Add to dashboard Cite

The use of fixed-dose combination pain relief has the potential to enhance analgesic efficacy. The pharmacokinetic properties of oral medication can be altered by many factors, including food, concomitant medications, and drug formulation. During the present study the pharmacokinetic parameters of an acetaminophen and ibuprofen combination was tested in four formulations. Testing was performed in two clinical trials examining either fasting or fed dosing conditions in healthy male participants. Both trials were single center, open-label, randomized, single dose studies with a four-way crossover design to compare an oral suspension product, a sachet product, and two different tablet formulations (FDC500/150 and FDC325/97.5). Each dose contained acetaminophen 975-1000 mg and ibuprofen 292.5-300 mg. A total of 26 participants completed the fasting study, while 28 completed the fed study. The absorption limits of different formulations of acetaminophen and ibuprofen were within the 80-125% bioequivalence range in both fasting and fed conditions as measured by the area under the plasma concentrationtime curve from time zero to the time of the last measurable plasma concentration (AUC (0-t)) and the area under the curve from time zero to infinity (AUC (0-∞)). The maximum measured plasma concentration (C max) for the two tablet formulations were bioequivalent in fed conditions for both acetaminophen and ibuprofen, while in fasting conditions ibuprofen was also bioequivalent. Food reduced the C max and increased the time at which maximum measured plasma concentration occurred (t max) of both acetaminophen and ibuprofen. This effect was largest in the sachet and oral suspension formulations, likely due to the drug being dissolved prior to administration, conferring more rapid absorption from the gastrointestinal tract. All treatments were well tolerated, with no treatment-emergent adverse events occurring. Overall, differing formulations and fasting conditions can alter the pharmacokinetic parameters C max , AUC (0-t) , AUC (0-∞) and t max of acetaminophen and ibuprofen combinations although the overall absorption remains bioequivalent.

show abstract

Gastrointestinal Adverse Reactions from Ibuprofen

Rainsford

Bjarnason

2015

Ibuprofen

View full text Add to dashboard Cite

Untitled

Cited by 33 publications

References 9 publications

Regional Distribution and Kinetics of Inhaled Pharmaceuticals

Regional Distribution and Kinetics of Inhaled Pharmaceuticals

A Single Dose, Four-Way, Open-Label Bioavailability Study of Oral Acetaminophen and Ibuprofen Combinations (Maxigesic®) under both Fasting and Fed Conditions

Gastrointestinal Adverse Reactions from Ibuprofen

Contact Info

Product

Resources

About